In subjects with early RA, different combinations of DMARDs led to a reduction in disease activity, along with favorable modifications of HDL particles in their structure and functional capacity, quantified by their composition of apoA-1, MPO, and PON1 [100]. This evidence concerns the gene PON1 and rheumatoid arthritis.